99 related articles for article (PubMed ID: 9219827)
1. In situ T-cell responses in a primary regressive melanoma and subsequent metastases: a comparative analysis.
Carcelain G; Rouas-Freiss N; Zorn E; Chung-Scott V; Viel S; Faure F; Bosq J; Hercend T
Int J Cancer; 1997 Jul; 72(2):241-7. PubMed ID: 9219827
[TBL] [Abstract][Full Text] [Related]
2. [Comparative analysis of the immune response in a case of primary regressive melanoma followed by gastric metastasis].
Hercend T; Zorn E; Carcelain G; Rouas N
Bull Acad Natl Med; 1995 Mar; 179(3):677-90; discussion 691-2. PubMed ID: 7648307
[TBL] [Abstract][Full Text] [Related]
3. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
Yamshchikov GV; Mullins DW; Chang CC; Ogino T; Thompson L; Presley J; Galavotti H; Aquila W; Deacon D; Ross W; Patterson JW; Engelhard VH; Ferrone S; Slingluff CL
J Immunol; 2005 Jun; 174(11):6863-71. PubMed ID: 15905528
[TBL] [Abstract][Full Text] [Related]
4. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion.
Zorn E; Hercend T
Eur J Immunol; 1999 Feb; 29(2):602-7. PubMed ID: 10064076
[TBL] [Abstract][Full Text] [Related]
5. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
[TBL] [Abstract][Full Text] [Related]
6. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
[TBL] [Abstract][Full Text] [Related]
7. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation.
Zorn E; Hercend T
Eur J Immunol; 1999 Feb; 29(2):592-601. PubMed ID: 10064075
[TBL] [Abstract][Full Text] [Related]
8. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells.
Berger TG; Haendle I; Schrama D; Lüftl M; Bauer N; Pedersen LØ; Schuler-Thurner B; Hohenberger W; Straten Pt Pt; Schuler G; Becker JC
Int J Cancer; 2004 Aug; 111(2):229-37. PubMed ID: 15197776
[TBL] [Abstract][Full Text] [Related]
9. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
10. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
12. Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage.
Maeurer MJ; Hurd S; Martin DM; Storkus WJ; Lotze MT
Cancer J Sci Am; 1995; 1(2):162-70. PubMed ID: 9166469
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
14. HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer.
Hoshino T; Seki N; Kikuchi M; Kuramoto T; Iwamoto O; Kodama I; Koufuji K; Takeda J; Itoh K
Int J Cancer; 1997 Mar; 70(6):631-8. PubMed ID: 9096641
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
Al-Batran SE; Rafiyan MR; Atmaca A; Neumann A; Karbach J; Bender A; Weidmann E; Altmannsberger HM; Knuth A; Jäger E
Cancer Res; 2005 May; 65(9):3937-41. PubMed ID: 15867394
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation.
Wankowicz-Kalinska A; Mailliard RB; Olson K; Graham F; Edington H; Kirkwood JM; Martinek S; Das PK; Storkus WJ
Melanoma Res; 2006 Apr; 16(2):165-74. PubMed ID: 16567972
[TBL] [Abstract][Full Text] [Related]
17. Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.
Aris M; Bravo AI; Pampena MB; Blanco PA; Carri I; Koile D; Yankilevich P; Levy EM; Barrio MM; Mordoh J
Front Immunol; 2018; 9():955. PubMed ID: 29774030
[TBL] [Abstract][Full Text] [Related]
18. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.
Kalaora S; Wolf Y; Feferman T; Barnea E; Greenstein E; Reshef D; Tirosh I; Reuben A; Patkar S; Levy R; Quinkhardt J; Omokoko T; Qutob N; Golani O; Zhang J; Mao X; Song X; Bernatchez C; Haymaker C; Forget MA; Creasy C; Greenberg P; Carter BW; Cooper ZA; Rosenberg SA; Lotem M; Sahin U; Shakhar G; Ruppin E; Wargo JA; Friedman N; Admon A; Samuels Y
Cancer Discov; 2018 Nov; 8(11):1366-1375. PubMed ID: 30209080
[TBL] [Abstract][Full Text] [Related]
19. Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.
Donia M; Andersen R; Kjeldsen JW; Fagone P; Munir S; Nicoletti F; Andersen MH; Thor Straten P; Svane IM
Cancer Res; 2015 Sep; 75(18):3747-59. PubMed ID: 26183926
[TBL] [Abstract][Full Text] [Related]
20. HLA-B-restricted, CD8+ cytolytic human T cell clones derived from a melanoma-invaded lymph node.
Nakashima M; Watanabe T; Koprowski H; Steplewski Z
Hybridoma; 1996 Apr; 15(2):147-54. PubMed ID: 8743295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
